K
40.59
0.52 (1.30%)
| Penutupan Terdahulu | 40.07 |
| Buka | 40.32 |
| Jumlah Dagangan | 228,845 |
| Purata Dagangan (3B) | 433,900 |
| Modal Pasaran | 3,076,549,888 |
| Harga / Pendapatan (P/E TTM) | 90.20 |
| Harga / Pendapatan (P/E Ke hadapan) | 31.55 |
| Harga / Jualan (P/S) | 5.46 |
| Harga / Buku (P/B) | 6.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Kiniksa Pharmaceuticals, Ltd. | Menurun | Menaik |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.13 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.80% |
| % Dimiliki oleh Institusi | 97.31% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (TD Cowen, 47.82%) | Beli |
| Median | 50.00 (23.18%) | |
| Rendah | 44.00 (Wedbush, 8.40%) | Beli |
| Purata | 50.80 (25.15%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 37.47 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 29 Oct 2025 | 55.00 (35.50%) | Beli | 37.38 |
| Citigroup | 17 Oct 2025 | 50.00 (23.18%) | Beli | 38.64 |
| Wedbush | 13 Oct 2025 | 44.00 (8.40%) | Beli | 37.03 |
| TD Cowen | 29 Sep 2025 | 60.00 (47.82%) | Beli | 38.77 |
| Wells Fargo | 25 Sep 2025 | 45.00 (10.86%) | Beli | 35.51 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London |
| 28 Oct 2025 | Pengumuman | Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution |
| 23 Oct 2025 | Pengumuman | Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 |
| 17 Oct 2025 | Pengumuman | Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |